4.4K(top 0.1%)
papers
106.9K(top 0.1%)
citations
133(top 1%)
h-index
218(top 1%)
g-index
6.4K
all documents
128.7K
doc citations
6.7K
citing journals

Top Articles

#TitleJournalYearCitations
1Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology20111,388
2A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)Journal of Thoracic Oncology20141,187
3Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology2001987
4Identification of genomic alterations in oesophageal squamous cell cancerNature2014935
54th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)Annals of Oncology2018929
6Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019JAMA Oncology2022919
7A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cellsNature Medicine2006898
8A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma PatientsCancer Research2010882
95th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology2020854
10Classification and prediction of survival in hepatocellular carcinoma by gene expression profilingHepatology2004834
11Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer GroupJournal of Clinical Oncology2003720
12Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2015604
13METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinomaMolecular Cancer2019563
14Genomic and molecular characterization of esophageal squamous cell carcinomaNature Genetics2014543
15OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerAnnals of Oncology2019532
16Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growthProceedings of the National Academy of Sciences of the United States of America2011507
17Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitisMolecular Carcinogenesis2011501
18Integration of oncology and palliative care: a Lancet Oncology CommissionLancet Oncology, The2018501
19IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and SignaturesFrontiers in Immunology2021494
20Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast CancerJournal of Clinical Oncology2010470
21Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialLancet Oncology, The2014443
22Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19Journal of Medical Virology2020442
23Three-dimensional printing of Hela cells for cervical tumor model in vitroBiofabrication2014440
24The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancerCancer Communications2019431
25Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology2018429
26Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer PatientsMicrobial Ecology2013423
27Punctuated copy number evolution and clonal stasis in triple-negative breast cancerNature Genetics2016410
28Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trialLancet Oncology, The2020404
29Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinomaNature Genetics2011397
30Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialLancet Oncology, The2013397
31Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyLancet Oncology, The2020389
32The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021Cancer Communications2021385
33Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaJAMA - Journal of the American Medical Association2021376
34Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society ClassificationArchives of Pathology and Laboratory Medicine2013368
35Integrative Proteomic Characterization of Human Lung AdenocarcinomaCell2020352
36A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han ChineseNature Genetics2011346
37Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancerCancer Cell2021343
38CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeCancer Discovery2018340
39LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancerCancer Communications2021340
40The global implications of diabetes and cancerLancet, The2014336
41Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell LymphomaJournal of Clinical Oncology2006331
42Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non–small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)International Journal of Radiation Oncology Biology Physics2006328
43Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumorsJournal of Hematology and Oncology2016324
44Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology Biology Physics2015314
45DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatinProceedings of the National Academy of Sciences of the United States of America2014313
46Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell CarcinomaAmerican Journal of Human Genetics2015301
47Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in AsiaNature Genetics2012293
48Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCJournal of Thoracic Oncology2020290
49Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trialLancet Oncology, The2019279
50MicroRNA-10b Promotes Migration and Invasion through KLF4 in Human Esophageal Cancer Cell LinesJournal of Biological Chemistry2010271